Research analysts at StockNews.com initiated coverage on shares of GlycoMimetics (NASDAQ:GLYC – Get Free Report) in a report released on Thursday. The firm set a “hold” rating on the biotechnology company’s stock. Separately, HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of GlycoMimetics in a report on Thursday, August […]